Brief: Tenax Therapeutics Provides 2023 Business Update
12/04/2023 14:00
April 12 (Reuters) - Tenax Therapeutics Inc TENX.O :
* TENAX THERAPEUTICS PROVIDES 2023 BUSINESS UPDATE
* TENAX THERAPEUTICS INC - EXPECTS TO INITIATE A PHASE 3
TRIAL OF
ORAL LEVOSIMENDAN IN PH-HFPEF IN 2023
* TENAX THERAPEUTICS-TO PRIORITIZE CLINICAL DEVELOPMENT OF
TNX-103
FOR TREATMENT OF PULMONARY HYPERTENSION & HEART FAILURE WITH
PRESERVED EJECTION FRACTION
Source text for Eikon: ID:nGNX7ycdyg
Further company coverage: TENX.O
((Reuters.Briefs@thomsonreuters.com;))